Literature DB >> 17704886

Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35.

A L DePaula1, A L V Macedo, N Rassi, C A Machado, V Schraibman, L Q Silva, A Halpern.   

Abstract

BACKGROUND: Type 2 diabetes mellitus (T2DM) is a common disease with numerous complications. Bariatric surgery is an efficient procedure for controlling T2DM in morbidly obese patients. In T2DM, the incretin effect is either greatly impaired or absent. This study aimed to evaluate the preliminary results from interposing a segment of ileum into the proximal jejunum associated with a sleeve or diverted sleeve gastrectomy to control T2DM in patients with a body mass index (BMI) less than 35 kg/m(2).
METHODS: For this study, 39 patients (16 women and 23 men) underwent two laparoscopic procedures comprising different combinations of ileal interposition into the proximal jejunum via a sleeve or diverted sleeve gastrectomy. The mean age of these patients was 50.3 years (range, 36-66 years). The mean BMI was 30.1 kg/m(2) (range, 23.4-34.9 kg/m(2)). All the patients had a diagnosis of T2DM that had persisted for at least 3 years and evidence of stable treatment with oral hypoglycemic agents or insulin for at least 12 months. The mean duration of T2DM was 9.3 years (range, 3-22 years).
RESULTS: The mean operative time was 185 min, and the median hospital stay was 4.3 days. Four major complications occurred in the short term (30-days), and the mortality rate was 2.6%. The mean postoperative follow-up period was 7 months (range, 4-16 months), and the mean percentage of weight loss was 22%. The mean postoperative BMI was 24.9 kg/m(2) (range, 18.9-31.7 kg/m(2)). An adequate glycemic control was achieved for 86.9% of the patients, and 13.1% had important improvement. The patients whose glycemia was not normalized were using a single oral hypoglycemic agent. No patient needed insulin therapy postoperatively. All the patients except experienced normalization of their cholesterol levels. Targeted triglycerides levels were achieved by 71% of the patients, and hypertension was controlled for 95.8%.
CONCLUSIONS: The laparoscopic ileal interposition via either a sleeve gastrectomy or diverted sleeve gastrectomy seems to be a promising procedure for the control of T2DM and the metabolic syndrome. A longer follow-up period is needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17704886     DOI: 10.1007/s00464-007-9472-9

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  46 in total

Review 1.  Insulin resistance is not necessarily an essential component of type 2 diabetes.

Authors:  J E Gerich
Journal:  J Clin Endocrinol Metab       Date:  2000-06       Impact factor: 5.958

2.  The mechanisms of surgical treatment of type 2 diabetes.

Authors:  Edward Eaton Mason
Journal:  Obes Surg       Date:  2005-04       Impact factor: 4.129

3.  Standards of medical care in diabetes--2006.

Authors: 
Journal:  Diabetes Care       Date:  2006-01       Impact factor: 19.112

Review 4.  Effect of dietary lipid on insulin action. Clinical studies.

Authors:  B A Swinburn
Journal:  Ann N Y Acad Sci       Date:  1993-06-14       Impact factor: 5.691

5.  Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study.

Authors:  Kusal Wickremesekera; Geoff Miller; Tissa Desilva Naotunne; Graham Knowles; Richard S Stubbs
Journal:  Obes Surg       Date:  2005-04       Impact factor: 4.129

6.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

7.  Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery.

Authors:  Geoffrey J Service; Geoffrey B Thompson; F John Service; James C Andrews; Maria L Collazo-Clavell; Ricardo V Lloyd
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

8.  Different aetiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects.

Authors:  P Arner; T Pollare; H Lithell
Journal:  Diabetologia       Date:  1991-07       Impact factor: 10.122

Review 9.  Incretins, insulin secretion and Type 2 diabetes mellitus.

Authors:  T Vilsbøll; J J Holst
Journal:  Diabetologia       Date:  2004-02-13       Impact factor: 10.122

10.  Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus.

Authors:  Ronald H Clements; Quintin H Gonzalez; Calvin I Long; Gary Wittert; Henry L Laws
Journal:  Am Surg       Date:  2004-01       Impact factor: 0.688

View more
  60 in total

1.  Roux-en-Y gastric bypass promotes expression of PDX-1 and regeneration of beta-cells in Goto-Kakizaki rats.

Authors:  Zhen Li; Hong-Ya Zhang; Lu-Xian Lv; Dong-Fei Li; Jing-Xing Dai; Ou Sha; Wen-Qiang Li; Yu Bai; Lin Yuan
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  Metabolic laparoscopic gastric bypass for obese patients with type 2 diabetes.

Authors:  Mário Nora; Marta Guimarães; Rui Almeida; Paulo Martins; Gil Gonçalves; Maria José Freire; Tiago Ferreira; Cláudia Freitas; Mariana P Monteiro
Journal:  Obes Surg       Date:  2011-11       Impact factor: 4.129

3.  Sleeve gastrectomy plus side-to-side jejunoileal anastomosis for the treatment of morbid obesity and metabolic diseases: a promising operation.

Authors:  John Melissas; Anastasia Peppe; John Askoxilakis; Efstathios Dimitriadis; John Grammatikakis
Journal:  Obes Surg       Date:  2012-07       Impact factor: 4.129

4.  Thirty-day morbidity and mortality of the laparoscopic ileal interposition associated with sleeve gastrectomy for the treatment of type 2 diabetic patients with BMI <35: an analysis of 454 consecutive patients.

Authors:  Aureo L DePaula; Alessandro Stival; Alfredo Halpern; Sergio Vencio
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

5.  Diabetes remission and insulin secretion after gastric bypass in patients with body mass index <35 kg/m2.

Authors:  Wei-Jei Lee; Keong Chong; Chih-Yen Chen; Shu-Chun Chen; Yi-Chih Lee; Kong-Han Ser; Lee-Ming Chuang
Journal:  Obes Surg       Date:  2011-07       Impact factor: 4.129

6.  The First International Consensus Summit for Sleeve Gastrectomy (SG), New York City, October 25-27, 2007.

Authors:  Mervyn Deitel; Ross D Crosby; Michel Gagner
Journal:  Obes Surg       Date:  2008-05       Impact factor: 4.129

7.  Surgery for diabetes at lower BMI: some caution.

Authors:  Mervyn Deitel
Journal:  Obes Surg       Date:  2008-08-30       Impact factor: 4.129

8.  Ileal interposition improves glucose tolerance in low dose streptozotocin-treated diabetic and euglycemic rats.

Authors:  April D Strader; Trine Ryberg Clausen; Sean Z Goodin; Donna Wendt
Journal:  Obes Surg       Date:  2008-11-07       Impact factor: 4.129

Review 9.  Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence?

Authors:  Mousumi Bose; Blanca Oliván; Julio Teixeira; F Xavier Pi-Sunyer; Blandine Laferrère
Journal:  Obes Surg       Date:  2008-09-27       Impact factor: 4.129

10.  Nutrient-driven incretin secretion into intestinal lymph is different between diabetic Goto-Kakizaki rats and Wistar rats.

Authors:  Tammy L Kindel; Qing Yang; Stephanie M Yoder; Patrick Tso
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-12-04       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.